纳武利尤单抗-瑞拉利单抗双免疫检查点阻断在晚期黑色素瘤的真实世界经验
该多中心回顾性研究纳入以色列10个肿瘤中心的117例不可切除或转移性黑色素瘤患者,一线接受纳武利尤单抗-瑞拉利单抗治疗。队列较关键试验更老更脆弱(中位年龄75岁,38%≥80岁),客观缓解率69.8%(完全缓解率43.6%),中位无进展生存期18.6个月,12个月总生存率74.1%,3-4级不良事件发生率11%,因毒性停药14.5%。
要点
- 真实世界队列较临床试验更老更脆弱,但纳武利尤单抗-瑞拉利单抗仍显示高缓解率和持久疾病控制。
- 客观缓解率69.8%,完全缓解率43.6%,中位无进展生存期18.6个月,12个月总生存率74.1%。
- 肝和/或骨转移及既往新辅助或辅助治疗与更差结局相关,≥80岁患者毒性停药比例更高。
核心结论
- 在常规临床实践中,纳武利尤单抗-瑞拉利单抗尽管用于较临床试验更老更脆弱的人群,仍表现出高缓解率和持久疾病控制,支持其作为一线选择,同时识别出可能受益于替代策略的预后较差亚组。
研究设计与样本
- 多中心回顾性研究,纳入以色列10个肿瘤中心的117例不可切除或转移性黑色素瘤成人患者,一线接受纳武利尤单抗-瑞拉利单抗治疗,评估总生存期、无进展生存期、黑色素瘤特异性生存期、客观缓解率和安全性,并用多变量分析探索结局预测因素。
主要发现
- 队列中位年龄75岁,38%患者年龄≥80岁,较关键临床试验人群更老且临床更脆弱。
- 客观缓解率为69.8%,其中完全缓解率为43.6%。
- 中位无进展生存期为18.6个月,中位总生存期和黑色素瘤特异性生存期未达到,12个月总生存率为74.1%。
- 3-4级不良事件发生率为11%,因毒性停药率为14.5%,主要发生在年龄≥80岁患者中。
- 多变量分析显示肝和/或骨转移及既往新辅助或辅助治疗与更差结局相关,并观察到高于预期的神经毒性发生率。
临床怎么用
- 真实世界数据支持纳武利尤单抗-瑞拉利单抗作为晚期黑色素瘤一线治疗选择,尤其适用于较临床试验更老更脆弱的人群。
- 对存在肝和/或骨转移或既往接受过新辅助/辅助治疗的患者,应考虑其预后较差,可能需要替代策略。
- 对年龄≥80岁患者需密切监测毒性,因该亚组因毒性停药比例更高。
局限性
- 本研究为回顾性设计,可能存在选择偏倚和信息偏倚。
- 样本量有限(117例),来自以色列10个中心,结果外推需谨慎。
- 中位总生存期和黑色素瘤特异性生存期未达到,长期随访数据尚不成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab-relatlimab, a dual immune checkpoint inhibitor targeting PD-1 and LAG-3, has demonstrated improved outcomes compared with nivolumab monotherapy in previously untreated advanced melanoma. However, real-world data in broader and less selected populations remain limited. METHODS: We conducted a multicenter retrospective study across 10 oncology centers in Israel, including adults with unresectable or metastatic melanoma treated with first-line nivolumab-relatlimab. Endpoints included overall survival (OS), progression-free survival (PFS), melanoma-specific survival (MSS), objective response rate (ORR), and safety. Predictors of outcomes were explored using multivariable analyses. RESULTS: A total of 117 patients were included. The cohort was older and clinically frailer than those enrolled in pivotal trials (median age 75 years; 38% aged ≥80 years). The ORR was 69.8%, including a complete response rate of 43.6%. Median PFS was 18.6 months, while median OS and MSS were not reached; 12-month OS was 74.1%. Grade 3-4 adverse events occurred in 11% of patients, and treatment discontinuation due to toxicity in 14.5%, predominantly among patients aged ≥80 years. In multivariable analyses, liver and/or bone metastases and prior neo- or adjuvant therapy were associated with inferior outcomes. A higher-than-anticipated rate of neurologic toxicity was observed. CONCLUSIONS: In routine clinical practice, nivolumab-relatlimab demonstrated high response rates and durable disease control despite an older and frailer population than in clinical trials. These findings support its use as a frontline option while identifying subgroups with poorer outcomes who may benefit from alternative strategies.
引用
- Asher N, Avner M, Goldberg N, et al. Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma. Eur J Cancer. 2026. PMID: 42735459. doi:10.1016/j.ejca.2026.117047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。